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A B S T R A C T   
Background: The Corona-Score is one of the first and most widely used predictive model for coronavirus 2 (SARS- 
CoV-2) infection. The purpose of this study was to validate the performance of Corona-Score in a cohort of 
Pakistani patients pursuing care for suspected infection. 
Methods: After seeking institution’s ethical committee exemption, results of serum lactate dehydrogenase (LDH), 
C-reactive protein (CRP), ferritin, absolute lymphocyte and neutrophil counts, chest x-ray findings and de-
mographics of suspected COVID-19 cases with respiratory symptoms were recouped from electronic medical 
record. The pre-validated score as proposed by Kurstjens S et al., was calculated. The subjects were divided into 
SARS-CoV-2 positive and negative on the basis of reverse transcription-polymerase chain reaction (RT-PCR) 
findings. Median and interquartile range (IQR) was calculated for the score in the two groups and the difference 
was assessed using the independent sample median test. Receiver operating characteristics (ROC) curve analysis 
was plotted. Statistical analyses were carried out using SPSS 26, with statistical significance set at p value < 0.05. 
Results: A total of sixty cases, 30 (50%) RT-PCR positive and 30 (50%) negative with a median Corona-Score of 
3.5 (IQR: 0–6) and 1.5 (IQR: 0–4) respectively, were evaluated. A p-value of 0.61 showing no statistically sig-
nificant between group differences was observed. The area under the curve of Corona-Score in our population of 
patients was 0.59 (95% CI: 0.45–0.74). Using the cut-off values of four originally identified by Kurstjens et al. the 
model displayed 43.3% sensitivity and 70% specificity with an overall accuracy of 56.67%. 
Conclusion: Corona-Score displayed a lower diagnostic accuracy which may be attributable to the different ge-
netic framework, viral strain and severity of the disease in Pakistanis compared to the population where this 
score was originally validated. However, large multi-center studies across the country are dire need of time to 
evaluate the score in overly exhausted health care setup and limited availability of PCR testing.   
1. Introduction 
The novel Coronavirus disease 2019 (COVID-19), caused by severe 
acute respiratory syndrome coronavirus 2 (SARS-CoV-2), after its origin 
in China in 2019, became a global pandemic in 2020 [1]. The disease 
can present as mild, flu-like illness, to critical condition requiring 
intensive care admission and mechanical ventilation [2,3]. The diag-
nosis of COVID-19 is still clearly based on detection of SARS-CoV-2 RNA 
in upper or lower respiratory tract specimens via nucleic acid amplifi-
cation tests (NAATs) [4]. However, these techniques have a few crucial 
disadvantages, such as the relatively low diagnostic sensitivity in 
nasopharyngeal swabs, shortage of testing materials and personnel, as 
well as time consuming, which constitute issues for purposes of huge 
populace screening [5]. 
Clinical laboratories have provided a significant contribution to-
wards diagnosis of COVID-19. To accelerate the diagnostic process, a 
point-based algorithm, the Corona-Score, was developed [6]. It is one of 
the first and most widely used predictive model that includes age, 
gender, chest X-ray and five laboratory investigations: lactate dehy-
drogenase (LDH), C-reactive protein (CRP), ferritin, and neutrophil and 
lymphocyte counts. This algorithm has the ability to predict whether a 
patient presenting with respiratory symptoms is probable to have 
COVID-19. A current study utilizing the Corona-Score in The 
Netherlands showed 91% accuracy, 96% sensitivity, and 95% specificity 
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for differentiating patients testing positive or negative for SARS-CoV-2 
by NAAT [6]. In fear of a shortage of testing capacity, embracing this 
algorithm could diminish the number of patients for whom RT-PCR 
testing is required. Moreover, in already resource constrained health 
care set ups with limited testing capacities in majority of the Indo-Pak 
sub-continent can facilitate rapid decision making in triage. 
Although these data are inspiring, the model needs to be validated in 
other clinical and healthcare settings. Therefore, the purpose of this 
study was to evaluate the performance of Corona-Score in a cohort of 
Pakistani patients pursuing care for suspected COVID-19 infection. 
2. Material and methods 
The study was conducted at the Section of Chemical Pathology in 
collaboration with the Section of Molecular Pathology, Department of 
Pathology and Laboratory Medicine, Aga Khan University (AKU), Kar-
achi, Pakistan, from August 2020 to January 2021. Permission form 
AKU’s Ethical Review committee was sought. The subjects were divided 
into SARS-CoV-2 positive and negative on the basis of reverse 
transcription-polymerase chain reaction (RT-PCR) results on a standard- 
of-care nasopharyngeal swab. 
Retrospective biochemical, hematological and imaging data was 
retrieved from the Integrated Laboratory Management System (ILMS). 
Biochemical parameters retrieved included serum LDH, CRP and 
ferritin. Hematological parameters recovered included absolute 
neutrophil and lymphocyte count. Presence of infiltrates on chest X-ray 
was the only radiological parameter included. The laboratory services at 
AKU operates according to the highest degree of quality and are 
accredited by Joint Commission International (JCIA) and College of 
American Pathologists (CAP). 
The pre-validated score as proposed by Kurstjens S et al. was calcu-
lated using Microsoft Excel for windows [6]. According to the 
Corona-Score instructions, concentrations of ferritin were multiplied by 
a harmonization factor of 1.2 for Siemens equipment. Based on age, 
gender, biochemical and radiological data scores were assigned to each 
parameter according to a pre-defined criteria as outlined by Kurstjens 
et al. [6]. The Corona-Score is obtained by the summation of the score 
for each parameter. The final score is calculated from a minimum of 0 to 
a maximum of 14 points. 
Median and interquartile range (IQR) was calculated for the score in 
the two groups and the difference was assessed using the independent 
sample median test. Receiver operating characteristics (ROC) curve 
analysis was plotted. Statistical analyses were carried out using Statis-
tical Package for the Social Sciences (SPSS) version 26, with statistical 
significance set at p < 0.05. The study was exempted by the institutional 
ethical review committee of the AKU, Karachi (ERC#2020-5168-14099) 
with waiver of informed consent. The study was also registered with 
Chinese Clinical Trial Registry (Registration No: ChiCTR2100042375). 
Furthermore, this work has been reported in line with the STROCSS 
criteria [7]. 
3. Results 
A total of 60 cases i.e. 30 (50%) positive and 30 (50%) negative by a 
nasopharyngeal swab RT-PCR testing were evaluated. The distribution 
of gender amongst RT-PCR positive and negative groups are shown in 
Table 1.The median Corona-Score of 3.5 (IQR: 0–6) was found in the RT- 
PCR positive group and 1.5 (IQR: 0–4) in the group that tested negative. 
The Corona-Score value was found to be elevated in participants with 
SARS-CoV-2 infection compared to those without. However, no statis-
tically significant between group differences was observed on 
independent-samples median test with a p-value of 0.605 as shown in 
Fig. 1. 
The area under the curve of Corona-Score in our population of pa-
tients was 0.59 (95% CI: 0.45–0.74). Using the cut-off values of 4 orig-
inally identified by Kurstjens et al. for their study population, the model 
displayed 43.3% sensitivity and 70% specificity with an overall accuracy 
of 56.67%. The results of ROC curve analysis is shown in Fig. 2. 
4. Discussion 
Thinking about the susceptible public health and healthcare system 
of Pakistan, and abrupt rise in number of infected cases, the country 
certainly has high possibility of morbidity and mortality associated with 
COVID-19. A number of interlaced reasons that put the Pakistani pop-
ulation at increased risk can be categorized into public reluctance 
(poverty, illiteracy, carelessness, rural lifestyle), healthcare personnel 
associated demurrals (reduced caregiver to patient ratio, inadequate 
knowledge and training of healthcare professionals, meager collabora-
tion) and ineffective organizations and authorities (unstable healthcare 
infrastructure, lack of infection control strategies, poor scrutiny system 
and resource constraints) [8]. Another issue is the restricted capacity of 
laboratories and it seems difficult to expand the laboratory facilities for 
large scale testing [9,10]. 
Population-scale testing for COVID-19 is probably the most ideal 
approach to restrict mortality rates. Large scale testing identifies and 
isolates infections quickly, restricting the virus’ spread and shielding 
susceptible populations [11]. The diagnosis of COVID-19 relies on 
detection of SARS-CoV-2 RNA in upper or lower respiratory tract spec-
imens via RT-PCR [12]. However, RT-PCR is time consuming and scar-
city of testing materials and facility enforce a grave hazard [13]. The 
Corona-Score, a point-based algorithm, incorporates routinely con-
ducted blood tests that are widely available and performed on auto-
mated platforms with very swift turn-around time [6]. The Corona-Score 
helps predict the likelihood of SARS-CoV-2 infection, and utilizing this 
score accelerates determination of isolation needs and also reduces 
Table 1 
Details of study subjects and median Corona-Score.   
RT-PCR Positive RT-PCR Negative 
Male (n) 12 13 
Female (n) 18 17 
Corona-Score (Median IQR) 3.5 (0–6) 1.5 (0–4) 
Age (years) 33.1±6.5 60.5±16.5  
Fig. 1. Independent sample median test for corona-score between groups p- 
value 0.605. 
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RT-PCR testing. It also eliminates the expertise and training of a person 
required to obtain a right, representative sample. Moreover, the PCR test 
can itself suffer from low diagnostic yield particularly false negatives in 
presence of classic sign and symptoms due to discrepancy in sample 
collection practices and timeline of infectivity, this is where corona 
score can produce vital information and necessitates protective mea-
sures for a likely true positive case. 
In this study the Corona Score exhibited an AUC of 0.59, which was 
considerably lower compared to the scores evaluation in Dutch and 
United States health care set ups [5,6]. The score was developed by 
Kurstjens S et al in a set of 967 Dutch patients seeking emergency 
care at multiple centers in Netherlands, using artificial intelligence 
based computational sampling, followed by validation of the 
model in 592 patients. The external validation by Lippi G et al in 
the United States of America, had also reported a lower AUC (0.74) 
and sensitivity (82%), but slightly higher specificity (96%) 
compared to the original Dutch cohort [5,6]. The authors have 
linked the variation to the populations’ specific differences, loca-
tion specific viral strains and the variance of health care structure 
and care provision between the three different health settings from 
Europe, United States and Asia. 
Findings of our study were reported from a single institute with 
a relatively small sample size which could be the limitations of our 
study and there exists a likelihood that significant improvement in 
diagnostic accuracy and predictive performance may arise with 
larger sample size. Secondly, as it was a retrospective analysis, 
differences in underlying patient co-morbidities could not be 
evaluated which may also contribute to these observation. Keeping 
in view the resource constraints and additional biochemical pa-
rameters, the score is unlikely to replace molecular analysis, but it 
can provide a practical supplement for assessing pre- and post-test 
probabilities and can serve as a screening tool for the control 
groups in COVID-19 clinical studies as suggested by Lippi G et al 
[5]. Moreover, we also propose to investigate the prognostic utility of 
corona score in a representative cohort to assist optimal intensive 
resource allocation and attain patient centered outcomes. 
5. Conclusion 
Corona-Score displayed a lower diagnostic accuracy which may be 
attributable to the different genetic framework, viral strain and severity 
of the disease in Pakistanis compared to the population where this score 
was originally validated. Corona Score is an easy-to-use algorithm for 
identification of Covid-19 patients with respiratory symptoms and needs 
to be further validated on a bigger sample size. Large multi-center 
studies across the country are dire need of time to evaluate the score 
in overly exhausted health care setup and limited availability of PCR 
testing. 
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